Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wassim Abida

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2021
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 StudyAndrea Loehr, Akash Patnaik, David Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
The New England Journal of Medicine|February 16, 2023
Rucaparib or Physician's Choice in Metastatic Prostate CancerKarim Fizazi, Josep M Piulats, M Neil Reaume, et al.
European Urology|May 13, 2026
IDH1 Mutations Are Associated with Favorable Outcomes in Prostate CancerLuka Cavka, Subhiksha Nandakumar, Qingqing Wu, et al.
European Urology|June 5, 2023
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2024
Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate CancerAndrew T Lenis, Vignesh Ravichandran, Samantha Brown, et al.
JCO Precision Oncology|October 5, 2020
Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate CancerDavid R Wise, Jeffrey A Schneider, Joshua Armenia, et al.
Science (New York, N.Y.)|May 26, 2022
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targetsFanying Tang, Duo Xu, Shangqian Wang, et al.
Cancer Cell|July 18, 2020
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate CancerZeda Zhang, Wouter R Karthaus, Young Sun Lee, et al.
Cancer Cell|March 30, 2020
Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin DysregulationZeda Zhang, Chuanli Zhou, Xiaoling Li, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2021
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 StudyAndrea Loehr, Akash Patnaik, David Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
The New England Journal of Medicine|February 16, 2023
Rucaparib or Physician's Choice in Metastatic Prostate CancerKarim Fizazi, Josep M Piulats, M Neil Reaume, et al.
European Urology|May 13, 2026
IDH1 Mutations Are Associated with Favorable Outcomes in Prostate CancerLuka Cavka, Subhiksha Nandakumar, Qingqing Wu, et al.
European Urology|June 5, 2023
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2024
Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate CancerAndrew T Lenis, Vignesh Ravichandran, Samantha Brown, et al.
JCO Precision Oncology|October 5, 2020
Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate CancerDavid R Wise, Jeffrey A Schneider, Joshua Armenia, et al.
Science (New York, N.Y.)|May 26, 2022
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targetsFanying Tang, Duo Xu, Shangqian Wang, et al.
Cancer Cell|July 18, 2020
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate CancerZeda Zhang, Wouter R Karthaus, Young Sun Lee, et al.
Cancer Cell|March 30, 2020
Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin DysregulationZeda Zhang, Chuanli Zhou, Xiaoling Li, et al.
Pageof 9